Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
2,565
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor

Philipp Bernhard Stabera Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, AustriaCorrespondence[email protected]
View further author information
,
Wojciech Jurczakb Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, PolandView further author information
,
Richard Greilc Laboratory for Immunological and Molecular Cancer Research, Salzburg Cancer Research Institute, Salzburg, AustriaView further author information
,
Vladan Vucinicd Department of Hematology and Internal Oncology, University Hospital Leipzig AöR, Leipzig, GermanyView further author information
,
Jan Moritz Middekee Medical Clinic 1, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyView further author information
,
Marco Montillof Hematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, ItalyView further author information
,
Talha Munirg Clinical Hematology, The Leeds Teaching Hospital, Leeds, UKView further author information
,
Peter Neumeisterh Clinical Department of Hematology, Medical University of Graz, Graz, AustriaView further author information
,
Johannes Schetelige Medical Clinic 1, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyView further author information
,
Stephan Stilgenbaueri Department of Internal Medicine III, Ulm University, Ulm, GermanyView further author information
,
Frank Striebelj MorphoSys AG, Planegg, GermanyView further author information
,
Maren Dirnberger-Hertweckj MorphoSys AG, Planegg, GermanyView further author information
,
Johannes Weiratherj MorphoSys AG, Planegg, GermanyView further author information
,
Wolfram Bruggerj MorphoSys AG, Planegg, GermanyView further author information
,
Peter Kelemenj MorphoSys AG, Planegg, GermanyView further author information
,
Clemens-Martin Wendtnerk Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases, and Tropical Medicine, Munich Clinic Schwabing, Munich, GermanyView further author information
&
Jennifer Ann Woyachl Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
 show all
Pages 3440-3451 | Received 22 Dec 2020, Accepted 25 Jul 2021, Published online: 20 Aug 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.